Pneumococcal vaccine conjugate 13-valent - Beijing Minhai Biotechnology
Alternative Names: PCV-13 - Beijing Minhai Biotechnology; PCV13-DT/TT; PNEUMINVACLatest Information Update: 04 Apr 2025
At a glance
- Originator Beijing Minhai Biotechnology
- Class Conjugate vaccines; Pneumococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Pneumococcal infections
Most Recent Events
- 01 Nov 2024 Phase-III clinical trials in Pneumococcal infections (Prevention, In infants) in Indonesia (IM) (NCT06608199)
- 23 Sep 2024 Beijing Minhai Biotechnology plans to initiated a phase III trial for Pneumococcal infections (Prevention) in Indonesia (NCT06608199)
- 05 Sep 2022 Pneumococcal vaccine conjugate 13-valent is still in phase III trials for Pneumococcal infections (In infants, Prevention) in China (IM)